Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

TN PREMIER CARE LLC

NPI: 1487081758 · KODAK, TN 37764 · Pain Clinic/Center · NPI assigned 10/02/2013

$52K
Total Medicaid Paid
8,793
Total Claims
6,882
Beneficiaries
13
Codes Billed
2018-01
First Month
2018-10
Last Month

Provider Details

Authorized OfficialCLARKE, IAN (OWNER)
NPI Enumeration Date10/02/2013

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 8,793 $52K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 2,304 1,777 $19K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 939 819 $12K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,468 1,895 $10K
96103 2,346 1,811 $6K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 204 165 $2K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 67 51 $482.76
97032 314 238 $352.79
93922 17 15 $297.98
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 24 21 $211.95
95923 14 13 $195.27
95921 13 12 $189.65
99406 64 50 $55.50
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 19 15 $6.97